Trail: A sword for killing tumors

Current Medicinal Chemistry

Volumn 17, Issue 29, 2010, Pages 3309-3317

  Wang, S ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Apoptosis; Biomarker; Cancer therapy; DR4; Drug design; KILLER DR5; TNF receptor superfamily; Tumor necrosis factor (TNF) related apoptosis inducing ligand (TRAIL)

Indexed keywords

BIOLOGICAL MARKER; DEATH RECEPTOR 4; DEATH RECEPTOR 5; HISTONE DEACETYLASE INHIBITOR; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR;

ANTIBODY DETECTION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER GENETICS; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER THERAPY; CARCINOGENESIS; DRUG DESIGN; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG SAFETY; GENE OVEREXPRESSION; GENE TARGETING; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MALIGNANT NEOPLASTIC DISEASE; MICROARRAY ANALYSIS; MONOTHERAPY; NONHUMAN; PROTEIN INTERACTION; SIGNAL TRANSDUCTION; TUMOR RESISTANCE;

EID: 77957965210     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986710793176285     Document Type: Article

References (98)

1. Danial, N. N.; Korsmeyer, S. J. Cell death: critical control points. Cell, 2004, 116, 205-219.
2. Hanahan, D.; Weinberg, R. A. The hallmarks of cancer. Cell, 2000, 100, 57-70.
3. Johnstone, R. W.; Ruefli, A. A.; Lowe, S. W. Apoptosis: a link between cancer genetics and chemotherapy. Cell, 2002, 108, 153-164.
4. Fesik, S. W. Promoting apoptosis as a strategy for cancer drug discovery. Nat. Rev. Cancer, 2005, 5, 876-885.
5. Lowe, S. W.; Ruley, H. E.; Jacks, T.; Housman, D. E. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell, 1993, 74, 957-967.
6. Lowe, S. W.; Schmitt, E. M.; Smith, S. W.; Osborne, B. A.; Jacks T. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature, 1993, 362, 847-849.
7. Lowe, S. W.; Bodis, S.; McClatchey, A.; Remington, L.; Ruley, H. E.; Fisher, D. E.; Housman, D. E.; Jacks, T. p53 status and the efficacy of cancer therapy in vivo. Science, 1994, 266, 807-810.
8. Wiley, S. R.; Schooley, K.; Smolak, P. J.; Din, W. S.; Huang, C. P.; Nicholl, J. K.; Sutherland, G. R.; Smith, T. D.; Rauch, C.; Smith, C. A.; Goodwin, R.G. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity, 1995, 3, 673-682.
9. Ashkenazi, A.; Pai, R. C.; Fong, S.; Leung, S.; Lawrence, D. A.; Marsters, S. A.; Blackie, C.; Chang, L.; McMurtrey, A. E.; Hebert, A.; DeForge, L.; Koumenis, I. L.; Lewis, D.; Harris, L.; Bussiere, J.; Koeppen, H.; Shahrokh, Z.; Schwall, R. H. Safety and antitumor activity of recombinant soluble Apo2 ligand. J. Clin. Invest., 1999, 104, 155-162.
10. Ashkenazi, A. Targeting death and decoy receptors of the tumornecrosis factor superfamily. Nat. Rev. Cancer, 2002, 2, 420-430.
11. Ashkenazi, A Directing cancer cells to self-destruct with proapoptotic receptor agonists. Nat. Rev. Drug Discov., 2008, 7, 1001-1017.
12. Johnstone, R. W.; Frew, A. J.; Smyth, M. J. The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat. Rev. Cancer, 2008, 8, 782-798.
13. Pitti, R. M.; Marsters, S. A.; Ruppert, S.; Donahue, C. J.; Moore, A.; Ashkenazi, A. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J. Biol. Chem., 1996, 271, 12687-12690.
14. Hymowitz, S. G.; Christinger, H. W.; Fuh, G.; Ultsch, M.; O'Connell, M.; Kelley, R. F.; Ashkenazi, A.; de Vos, A. M. Triggering cell death: the crystal structure of Apo2L/TRAIL in a complex with death receptor 5. Mol. Cell, 1999, 4, 563-571.
15. Mongkolsapaya, J.; Grimes, J. M.; Chen, N.; Xu, X. N.; Stuart, D. I.; Jones, E. Y.; Screaton, G. R. Structure of the TRAIL-DR5 complex reveals mechanisms conferring specificity in apoptotic initiation. Nat. Struct. Biol., 1999, 6, 1048-1053.
16. Cha, S. S.; Kim, M. S.; Choi, Y. H.; Sung, B. J.; Shin, N. K.; Shin, H. C.; Sung, Y. C.; Oh, B. H. 2.8 A° resolution crystal structure of human TRAIL, a cytokine with selective antitumor activity. Immunity, 1999, 11, 253-261.
17. Pan, G.; O'Rourke, K.; Chinnaiyan, A. M.; Gentz, R.; Ebner, R.; Ni, J.; Dixit, V.M. The receptor for the cytotoxic ligand TRAIL. Science, 1997, 276, 111-113.
18. Wu, G. S.; Burns, T. F.; McDonald, E. R; Jiang, W.; Meng, R.; Krantz, I. D.; Kao, G.; Gan, D. D.; Zhou, J. Y.; Muschel, R.; Hamilton, S. R.; Spinner, N. B.; Markowitz, S.; Wu, G.; El-Deiry, W. S. KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nat. Genet., 1997, 17, 141-143.
19. Pan, G.; Ni, J.; Wei, Y. F.; Yu, G.; Gentz, R.; Dixit, V. M. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science, 1997, 277, 815-818.
20. Sheridan, J. P.; Marsters, S. A.; Pitti, R. M.; Gurney, A.; Skubatch, M.; Baldwin, D.; Ramakrishnan, L.; Gray, C. L.; Baker, K.; Wood, W. I.; Goddard, A. D.; Godowski, P.; Ashkenazi, A. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science, 1997, 277, 818-821.
21. Walczak, H.; Degli-Esposti, M. A.; Johnson, R. S.; Smolak, P. J.; Waugh, J. Y.; Boiani, N.; Timour, M. S.; Gerhart, M. J.; Schooley, K. A.; Smith, C. A.; Goodwin, R. G.; Rauch, C. T. TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL. EMBO J., 1997, 16, 5386-5397.
22. Degli-Esposti, M. A.; Smolak, P. J.; Walczak, H.; Waugh, J.; Huang, C. P.; DuBose, R. F.; Goodwin, R. G.; Smith, C. A. Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family. J. Exp. Med., 1997, 186, 1165-1170.
23. Degli-Esposti, M. A.; Dougall, W. C.; Smolak, P. J.; Waugh, J. Y.; Smith, C. A.; Goodwin, R. G. The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. Immunity, 1997, 7, 813-820.
24. Marsters, S. A.; Sheridan, J. P.; Pitti, R. M.; Huang, A.; Skubatch, M.; Baldwin, D.; Yuan, J.; Gurney, A.; Goddard, A. D.; Godowski, P.; Ashkenazi, A. A novel receptor for Apo2L/TRAIL contains a truncated death domain. Curr. Biol., 1997, 7, 1003-1006.
25. Emery, J. G.; McDonnell, P.; Burke, M. B.; Deen, K. C.; Lyn, S.; Silverman, C.; Dul, E.; Appelbaum, E. R.; Eichman, C.; DiPrinzio, R.; Dodds, R. A.; James, I. E.; Rosenberg, M.; Lee, J. C.; Young, P. R. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J. Biol. Chem., 1998, 273, 14363-14367.
26. Wu, G. S.; Burns, T. F.; Zhan, Y.; Alnemri, E. S.; El-Deiry, W. S. Molecular cloning and functional analysis of the mouse homologue of the KILLER/DR5 tumor necrosis factor-related apoptosisinducing ligand (TRAIL) death receptor. Cancer Res., 1999, 59, 2770-2775.
27. Schneider, P.; Olson, D.; Tardivel, A.; Browning, B.; Lugovskoy, A.; Gong, D.; Dobles, M.; Hertig, S.; Hofmann, K.; Van Vlijmen, H.; Hsu, Y. M.; Burkly, L. C.; Tschopp, J.; Zheng, T. S. Identification of a new murine tumor necrosis factor receptor locus that contains two novel murine receptors for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). J. Biol. Chem., 2003, 278, 5444-5454.
28. Cretney, E.; Takeda, K.; Yagita, H.; Glaccum, M.; Peschon, J. J.; Smyth, M. J. Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice. J. Immunol., 2002, 168, 1356-1361.
29. Takeda, K.; Hayakawa, Y.; Smyth, M. J.; Kayagaki, N.; Yamaguchi, N.; Kakuta, S.; Iwakura, Y.; Yagita, H.; Okumura, K. Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells. Nat. Med., 2001, 7, 94-100.
30. Xu, J.; Zhou, J. Y.; Wu, G. S. Tumor necrosis factor-related apoptosis-inducing ligand is required for tumor necrosis factor alphamediated sensitization of human breast cancer cells to chemotherapy. Cancer Res., 2006, 66, 10092-10099.
31. Grosse-Wilde, A.; Voloshanenko, O.; Bailey, S. L.; Longton, G. M.; Schaefer, U.; Csernok, A. I.; Schütz, G.; Greiner, E. F.; Kemp, C. J.; Walczak, H. TRAIL-R deficiency in mice enhances lymph node metastasis without affecting primary tumor development. J. Clin. Invest., 2008, 118, 100-110.
32. Finnberg, N.; Klein-Szanto, A. J.; El-Deiry, W. S. TRAIL-R deficiency in mice promotes susceptibility to chronic inflammation and tumorigenesis. J. Clin. Invest., 2008, 118, 111-123.
33. Finnberg, N.; Gruber, J. J.; Fei, P.; Rudolph, D.; Bric, A.; Kim, S. H.; Burns, T. F.; Ajuha, H.; Page, R.; Wu, G. S.; Chen, Y.; McKenna, W. G.; Bernhard, E.; Lowe, S. Mak, T.; El-Deiry, W. S. DR5 knockout mice are compromised in radiation-induced apoptosis. Mol. Cell Biol., 2005, 25, 2000-2013.
34. Pai, S. I.; Wu, G. S.; Ozören, N.; Wu, L.; Jen, J.; Sidransky, D.; El-Deiry, W. S. Rare loss-of-function mutation of a death receptor gene in head and neck cancer. Cancer Res., 1998, 58, 3513-3518.
35. Wang, S.; El-Deiry, W. S. Inducible silencing of KILLER/DR5 in vivo promotes bioluminescent colon tumor xenograft growth and confers resistance to chemotherapeutic agent 5-fluorouracil. Cancer Res., 2004, 64, 6666-6672.
36. Laguinge, L. M.; Samara, R. N.; Wang, W.; El-Deiry, W. S.; Corner, G.; Augenlicht, L.; Mishra, L.; Jessup, J. M. DR5 receptor mediates anoikis in human colorectal carcinoma cell lines. Cancer Res., 2008, 68, 909-917.
37. Kelley, R. F.; Totpal, K.; Lindstrom, S. H.; Mathieu, M.; Billeci, K.; Deforge, L.; Pai, R.; Hymowitz, S. G.; Ashkenazi, A. Receptorselective mutants of apoptosis-inducing ligand 2/tumor necrosis factor-related apoptosis-inducing ligand reveal a greater contribution of death receptor (DR) 5 than DR4 to apoptosis signaling. J. Biol. Chem., 2005, 280, 2205-2212.
38. Ashkenazi, A.; Dixit, V. M. Death receptors: signaling and modulation. Science, 1998, 281, 1305-1308.
39. Scaffidi, C.; Fulda, S.; Srinivasan, A.; Friesen, C.; Li, F.; Tomaselli, K. J.; Debatin, K. M.; Krammer, P. H.; Peter, M. E. Two CD95 (APO-1/Fas) signaling pathways. EMBO J., 1998, 17, 1675-1687.
40. Barnhart, B. C.; Alappat, E. C.; Peter, M. E. The CD95 type I/type II model. Semin. Immunol., 2003, 15, 185-193.
41. Scaffidi, C.; Schmitz, I.; Zha, J.; Korsmeyer, S. J.; Krammer, P. H.; Peter, M. E. Differential modulation of apoptosis sensitivity in CD95 type I and type II cells. J. Biol. Chem., 1999, 274, 22532-22538.
42. Kohlhaas, S. L.; Craxton, A.; Sun, X. M.; Pinkoski, M. J.; Cohen, G. M. Receptor-mediated endocytosis is not required for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis. J. Biol. Chem., 2007, 282, 12831-12841.
43. Hu, W. H.; Johnson, H.; Shu, H. B. Tumor necrosis factor-related apoptosis-inducing ligand receptors signal NF-κB and JNK activation and apoptosis through distinct pathways. J. Biol. Chem., 1999, 274, 30603-30610.
44. Ravi, R.; Bedi, G. C, Engstrom, L. W, Zeng, Q, Mookerjee, B, Gélinas, C, Fuchs, E. J, Bedi, A. Regulation of death receptor expression and TRAIL/Apo2L-induced apoptosis by NF-κB. Nat. Cell Biol., 2001, 3, 409-416.
45. Varfolomeev, E.; Maecker, H.; Sharp, D.; Lawrence, D.; Renz, M.; Vucic, D.; Ashkenazi, A. Molecular determinants of kinase pathway activation by Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand. J. Biol. Chem., 2005, 280, 40599-40608.
46. Secchiero, P.; Gonelli, A.; Carnevale, E.; Milani, D.; Pandolfi, A.; Zella, D.; Zauli, G. TRAIL promotes the survival and proliferation of primary human vascular endothelial cells by activating the Akt and ERK pathways. Circulation, 2003, 107, 2250-2256.
47. Zauli, G.; Sancilio, S.; Cataldi, A.; Sabatini, N.; Bosco D.; Di Pietro, R. PI-3K/Akt and NF-κB/IκBα pathways are activated in Jurkat T cells in response to TRAIL treatment. J. Cell Physiol., 2005, 202, 900-911.
48. Micheau, O.; Tschopp, J. Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes. Cell, 2003, 114, 181-190.
49. Chaudhary, P. M.; Eby, M.; Jasmin, A.; Bookwalter, A.; Murray, J.; Hood, L. Death receptor 5, a new member of the TNFR family, and DR4 induce FADD dependent apoptosis and activate the NF-κB pathway. Immunity, 1997, 7, 821-830.
50. Romagnoli, M.; Desplanques, G.; Maïga, S.; Legouill, S.; Dreano, M.; Bataille, R.; Barillé-Nion, S. Canonical nuclear factor-κB pathway inhibition blocks myeloma cell growth and induces apoptosis in strong synergy with TRAIL. Clin. Cancer Res., 2007, 13, 6010-6018.
51. Clancy, L.; Mruk, K.; Archer, K.; Woelfel, M.; Mongkolsapaya, J.; Screaton, G.; Lenardo, M. J.; Chan, F. K. Preligand assembly domain-mediated ligand-independent association between TRAIL receptor 4 (TR4) and TR2 regulates TRAIL-induced apoptosis. Proc. Natl. Acad. Sci. USA, 2005, 102, 18099-18104.
52. Merino D.; Lalaoui, N.; Morizot, A.; Schneider, P.; Solary, E.; Micheau, O. Differential inhibition of TRAIL mediated DR5-DISC formation by decoy receptors 1 and 2. Mol. Cell Biol., 2006, 26, 7046-7055.
53. Wang, Y.; Quon, K. C.; Knee, D. A.; Nesterov, A.; Kraft, A. S. RAS, MYC, and sensitivity to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. Cancer Res., 2005, 65, 1615-1616.
54. Nieminen, A. I.; Partanen, J. I.; Hau, A.; Klefstrom, J. c-Myc primed mitochondria determine cellular sensitivity to TRAILinduced apoptosis. EMBO J., 2007, 26, 1055-1067.
55. Wagner K. W.; Punnoose, E. A.; Januario, T.; Lawrence, D. A.; Pitti, R. M.; Lancaster, K.; Lee, D.; von Goetz, M.; Yee, S. F.; Totpal, K.; Huw, L.; Katta, V.; Cavet, G.; Hymowitz, S. G.; Amler, L.; Ashkenazi, A. Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL. Nat. Med., 2007, 13, 1070-1077.
56. Lee, S. H.; Shin, M. S.; Kim, H. S.; Lee, H. K.; Park, W. S.; Kim, S. Y.; Lee, J.H.; Han, S. Y.; Park, J.Y.; Oh, R. R.; Jang, J. J.; Han, J.Y.; Lee, J. Y.; Yoo, N. J. Alterations of the DR5/TRAIL receptor 2 gene in non-small cell lung cancers. Cancer Res., 1999, 59, 5683-5686.
57. Lee S. H.; Shin, M. S.; Kim, H. S.; Lee, H. K.; Park, W. S.; Kim, S. Y.; Lee, J. H.; Han, S. Y.; Park, J. Y.; Oh, R. R.; Kang, C. S.; Kim, K. M.; Jang, J. J.; Nam, S.W.; Lee, J. Y.; Yoo, N. J. Somatic mutations of TRAIL-receptor 1 and TRAIL-receptor 2 genes in non-Hodgkin's lymphoma. Oncogene, 2001, 20, 399-403.
58. Fisher M. J.; Virmani, A. K.; Wu, L.; Aplenc, R.; Harper, J. C.; Powell, S. M.; Rebbeck, T. R.; Sidransky, D.; Gazdar, A. F.; El-Deiry, W. S. Nucleotide substitution in the ectodomain of trail receptor DR4 is associated with lung cancer and head and neck cancer. Clin. Cancer Res., 2001, 7, 1688-1697.
59. Shin, M. S.; Kim, H. S.; Lee, S. H.; Park, W. S.; Kim, S. Y.; Park, J. Y.; Lee, J. H.; Lee, S. K.; Lee, S. N.; Jung, S. S.; Han, J. Y.; Kim, H.; Lee, J. Y.; Yoo, N. J. Mutations of tumor necrosis factorrelated apoptosis-inducing ligand receptor 1 (TRAIL-R1) and receptor 2 (TRAIL-R2) genes in metastatic breast cancers. Cancer Res., 2001, 61, 4942-4946.
60. Bin L.; Thorburn, J.; Thomas, L. R.; Clark, P. E.; Humphreys, R.; Thorburn, A. Tumor-derived mutations in the TRAIL receptor DR5 inhibit TRAIL signaling through the DR4 receptor by competing for ligand binding. J. Biol. Chem., 2007, 282, 28189-28194.
61. MacFarlane, M.; Kohlhaas, S. L.; Sutcliffe, M. J.; Dyer, M. J.; Cohen, G. M. TRAIL receptor-selective mutants signal to apoptosis via TRAIL-R1 in primary lymphoid malignancies. Cancer Res., 2005, 65, 11265-11270.
62. van der Sloot, A. M.; Tur, V.; Szegezdi, E.; Mullally, M. M.; Cool, R. H.; Samali, A.; Serrano, L.; Quax, W. J. Designed tumor necrosis factor-related apoptosis-inducing ligand variants initiating apoptosis exclusively via the DR5 receptor. Proc. Natl. Acad. Sci. USA, 2006, 103, 8634-8639.
63. Tur V.; van der Sloot, A. M.; Reis, C. R.; Szegezdi, E.; Cool, R. H.; Samali, A.; Serrano, L.; Quax, W. J. DR4-selective tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) variants obtained by structure-based design. J. Biol.Chem., 2008, 283, 20560-20568.
64. Irmler M.; Thome, M.; Hahne, M.; Schneider, P.; Hofmann, K.; Steiner, V.; Bodmer, J. L.; Schröter, M.; Burns, K.; Mattmann, C.; Rimoldi, D.; French, L. E.; Tschopp J. Inhibition of death receptor signals by cellular FLIP. Nature, 1997, 388, 190-195.
65. Burns T. F.; El-Deiry W. S. Identification of inhibitors of TRAILinduced death (ITIDs) in the TRAIL-sensitive colon carcinoma cell line SW480 using a genetic approach. J. Biol. Chem., 2001, 276, 37879-37886.
66. Hopkins-Donaldson, S.; Ziegler, A.; Kurtz, S.; Bigosch, C.; Kandioler, D.; Ludwig, C.; Zangemeister-Wittke, U.; Stahel, R. Silencing of death receptor and caspase-8 expression in small cell lung carcinoma cell lines and tumors by DNA methylation. Cell Death. Differ., 2003, 10, 356-364.
67. Kataoka, T., Budd, R. C., Holler, N., Thome, M., Martinon, F., Irmler, M., Burns, K., Hahne, M., Kennedy, N., Kovacsovics, M., Tschopp, J. The caspase-8 inhibitor FLIP promotes activation of NF-κB and Erk signaling pathways. Curr. Biol., 2000, 10, 640-648.
68. Jin, Z.; Li, Y.; Pitti, R.; Lawrence, D.; Pham, V. C.; Lill, J. R.; Ashkenazi, A. Cullin3-based polyubiquitination and p62-dependent aggregation of caspase-8 mediate extrinsic apoptosis signaling. Cell, 2009, 137, 721-35.
69. Ricci, M. S.; Jin, Z.; Dews, M.; Yu, D.; Thomas-Tikhonenko, A.; Dicker, D. T.; El-Deiry, W. S. Direct repression of FLIP expression by c-myc is a major determinant of TRAIL sensitivity. Mol. Cell Biol., 2004, 24, 8541-8555.
70. Wang, Y.; Engels, I. H.; Knee, D. A.; Nasoff, M.; Deveraux, Q. L.; Quon, K. C. Synthetic lethal targeting of MYC by activation of the DR5 death receptor pathway. Cancer Cell, 2004, 5, 501-512.
71. Hall, M. A.; Cleveland, J. L. Clearing the TRAIL for Cancer Therapy. Cancer Cell, 2007, 12, 4-6.
72. Ricci, M. S.; Kim, S. H.; Ogi, K.; Plastaras, J. P.; Ling, J.; Wang, W, Jin, Z.; Liu, Y. Y.; Dicker, D.T.; Chiao, P. J.; Flaherty, K. T.; Smith, C. D.; El-Deiry, W. S. Reduction of TRAIL-induced Mcl-1 and cIAP2 by c-Myc or sorafenib sensitizes resistant human cancer cells to TRAIL-induced death. Cancer Cell, 2007, 12, 66-80.
73. Deng, Y.; Lin, Y.; Wu, X. TRAIL-induced apoptosis requires Baxdependent mitochondrial release of Smac/DIABLO. Genes Dev., 2002, 16, 33-45.
74. LeBlanc, H.; Lawrence, D.; Varfolomeev, E.; Totpal, K.; Morlan, J.; Schow, P.; Fong, S.; Schwall, R.; Sinicropi, D.; Ashkenazi, A. Tumor-cell resistance to death receptor--induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax. Nat. Med., 2002, 8, 274-281.
75. Wang, S.; El-Deiry, W. S. Requirement of p53 targets in chemosensitization of colonic carcinoma to death ligand therapy. Proc. Natl. Acad. Sci. USA, 2003, 100, 15095-15100.
76. Burikhanov, R.; Zhao, Y.; Goswami, A.; Qiu, S.; Schwarze, S.; Rangnekar, V. M. The tumor suppressor Par-4 activates an extrinsic pathway for apoptosis. Cell, 2009, 138, 377-388.
77. Ambros, V. The functions of animal microRNAs. Nature, 2004, 431, 350-355.
78. Bartel, D.P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell, 2004, 116, 281-297.
79. Garofalo, M.; Di Leva, G.; Romano, G.; Nuovo, G.; Suh, S. S.; Ngankeu, A.; Taccioli, C.; Pichiorri, F.; Alder, H.; Secchiero, P.; Gasparini, P.; Gonelli, A.; Costinean, S.; Acunzo, M.; Condorelli, G.; Croce, C. M. miR-221&222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation. Cancer Cell, 2009, 16, 498-509.
80. Travert, M.; Ame-Thomas, P.; Pangault, C.; Morizot, A.; Micheau, O.; Semana, G.; Lamy, T.; Fest, T, Tarte, K.; Guilaudeux, T. CD40 ligand protects from TRAIL-induced apoptosis in follicular lymphomas through NF-􀀁B activation and upregulation of c-FLIP and Bcl-XL. J. Immunol., 2008, 181, 1001-1011.
81. Mitsiades, N.; Mitsiades, C. S.; Poulaki, V.; Anderson, K. C.; Treon, S. P. Intracellular regulation of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human multiple myeloma cells. Blood, 2002, 99, 2162-2171.
82. Dida, F.; Li, Y.; Ivano, A.; Deguchi, T.; Azuma, E.; Komada, Y. Resistance to TRAIL-induced apoptosis caused by constitutional phosphorylation of AKT and PTEN in acute lymphoblastic leukemia cells. Exp. Hematol., 2008, 36, 1343-1353.
83. Schimmer, A. D.; Dalili, S.; Batey, R. A.; Riedl, S. J. Targeting XIAP for the treatment of malignancy. Cell Death Differ., 2006, 13, 179-188.
84. Secchiero, P.; Gonelli, A.; Miarnadola, P.; Melloni, E.; Zamai, I.; Celeghini, C. Tumor necrosis factor-related apoptosis-inducing ligand induces monocytic maturation of leukemic and normal myeloid precursors through a caspase-dependent pathway. Blood, 2002, 100, 2421-2429.
85. Sakoe, Y.; Sakoe, K.; Kirto, K.; Ozawa, K.; Komatsu, N. FOXO3A as a key molecule for all-trans retinoic acid-induced granulocytic differentiation and apoptosis in acute promyelocytic leukemia. Blood, 2010, [Epub ahead of print].
86. Lawrence, D.; Shahrokh, Z.; Marsters, S.; Achilles, K.; Shih, D.; Mounho, B.; Hillan, K.; Totpal, K.; DeForge, L.; Schow, P.; Hooley, J.; Sherwood, S.; Pai, R.; Leung, S.; Khan, L.; Gliniak, B.; Bussiere, J.; Smith, C. A.; Strom, S. S.; Kelley, S.; Fox, J. A.; Thomas, D.; Ashkenazi, A. Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat. Med., 2001, 7, 383-385.
87. Kim, S.H.; Kim, K.; Kwagh, J. G.; Dicker, D. T.; Herlyn, M.; Rustgi, A. K.; Chen, Y.; El-Deiry, W. S. Death induction by recombinant native TRAIL and its prevention by a caspase 9 inhibitor in primary human esophageal epithelial cells. J. Biol. Chem., 2004, 279, 40044-40052.
88. Jo, M.; Kim, T. H.; Seol, D. W.; Esplen, J. E.; Dorko, K.; Billiar, T. R.; Strom, S. C. Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosisinducing ligand. Nat. Med., 2000, 6, 564-567.
89. Herbst R. S. A Phase I safety and pharmacokinetic study in patients with advanced cancer treated with recombinant Apo2L/TRAIL, an apoptosis-inducing protein. J. Clin. Oncol. Abstr., 2006, 24, 3013.
90. Tolcher A. W.; Mita, M.; Meropol N. J.; von Mehren, M.; Patnaik, A.; Padavic, K.; Hill, M.; Mays, T.; McCoy, T.; Fox, N. L.; Halpern, W.; Corey, A.; Cohen, R. B. Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factorrelated apoptosis-inducing ligand receptor-1. J. Clin. Oncol., 2007, 25, 1390-1395.
91. Gliniak, B.; Le, T. Tumor necrosis factor-related apoptosisinducing ligand's antitumor activity in vivo is enhanced by the chemotherapeutic agent CPT-11. Cancer Res., 1999, 59, 6153-6158.
92. Wang, S.; El-Deiry, W. S. Requirement of p53 targets in chemosensitization of colonic carcinoma to death ligand therapy. Proc. Natl. Acad. Sci. USA, 2003, 100, 15095-15100.
93. Bolden, J. E.; Peart, M. J.; Johnstone, R. W. Anticancer activities of histone deacetylase inhibitors. Nat. Rev. Drug Discov., 2006, 5, 769-784.
94. Insinga, A.; Monestiroli, S.; Ronzoni, S.; Gelmetti, V.; Marchesi, F.; Viale, A.; Altucci, L.; Nervi, X. C.; Minucci, S.; Pelicci, P. G. Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. Nat. Med., 2005, 11, 71-76.
95. Lindemann, R. K.; Newbold, A.; Whitecross, K. F.; Cluse, L. A.; Frew, A. J.; Ellis, L.; Williams, S.; Wiegmans, A. P.; Dear, A. E.; Scott, C.L.; Pellegrini, M.; Wei, A.; Richon, V. M.; Marks, P. A.; Lowe, S.W.; Smyth, M. J.; Johnstone, R. W. Analysis of the apoptotic and therapeutic activities of histone deacetylase inhibitors by using a mouse model of B cell lymphoma. Proc. Natl. Acad. Sci. USA, 2007, 104, 8071-8076.
96. Zong, W. X.; Li, C.; Hatzivassiliou, G.; Lindsten, T.; Yu, Q. C.; Yuan, J.; Thompson, C. B. Bax and Bak can localize to the endoplasmic reticulum to initiate apoptosis. J. Cell Biol., 2003, 162, 59-69.
97. Scorrano, L.; Oakes, S. A.; Opferman, J. T.; Cheng, E. H.; Sorcinelli, M. D.; Pozzan, T.; Korsmeyer, S. J. BAX and BAK regulation of endoplasmic reticulum Ca2+: a control point for apoptosis. Science, 2003, 300, 135-9.
98. Boehning, D.; Patterson, R. L.; Sedaghat, L.; Glebova, N. O.; Kurosaki, T.; Snyder, S. H. Cytochrome c binds to inositol (1,4,5) trisphosphate receptors, amplifying calcium-dependent apoptosis. Nat. Cell Biol., 2003, 5, 1051-61.